Market Research Report
3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035
|Published by||ROOTS ANALYSIS||Product code||586194|
|Published||Content info||350 Pages
Delivery time: 1-2 business days
|3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035|
|Published: November 20, 2017||Content info: 350 Pages||
3D printing has garnered significant attention within the healthcare industry. The concept of 3D bioprinting was conceived in the late 1990s; since then, various industry stakeholders and academicians have undertaken several initiatives in order to further develop / improve this technology for a variety of applications. Organovo was the first company to enter the 3D bioprinting space by printing functional blood vessels in 2010. The company now offers 3D printed kidney and liver tissue models. There have been a number of other notable attempts to create fully functional 3D bioprinted tissues. For instance, in 2015, 3D Bioprinting Solutions became the first company to print and transplant a thyroid gland in a mouse. Subsequently, in the same year, Aspect Biosystems developed and commercialized 3D printed human respiratory tissue for clinical testing. In addition to these, other companies with commercialized tissue products include MEDPRIN, Poietis, and Sirris.
The current applications of 3D bioprinted products cater to various requirements within the pharmaceutical industry for clinical testing of therapeutic drugs. Owing to the evident interspecies differences, drug candidates that are shown to be efficacious in animal models often fail in humans. For such purposes, 3D bioprinting can be used to develop more accurate, human specific disease models. Further, there is a severe unmet need when it comes to organ transplants. Therefore, the ability to synthetically create organs for transplantation purposes is expected to generate a lot of interest amongst pharmaceutical / biotechnology players in the coming years.
The current market landscape of 3D bioprinting is characterized by the presence of nearly equal number of industry and non-industry players, featuring a number of startups and university spin-offs. Although there are several 3D bioprinting technologies already available, active efforts are being made to add to the intellectual property portfolio. The field has witnessed growing partnering activity and has also managed to capture the interest of both public and private sector investors.Despite certain challenges, several technical advancements and high unmet need of current patients waiting for organ transplants is anticipated to significantly drive future growth.
The ‘3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035' report provides a comprehensive study on the current market landscape of the 3D bioprinting industry, featuring an elaborate discussion on the future potential of this evolving market. The field has seen the emergence of many new players in the past few years; in fact, several well-known players of the 3D printing industry have broadened their focus to launch new initiatives specific to 3D bioprinting. Amongst other things, the report features:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target consumer segments, expected adoption rates and pricing, we have provided an informed estimate of the likely evolution of the opportunity within the market in the short to mid-term and long term, for the period 2018-2035. To account for the uncertainties associated with the development of 3D bioprinted products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Douglas Chrisey (Professor, Tulane University), Fanny Geraldo and Lisa Oliver (Researchers, University of Nantes), Glauco R. Souza (President and Chief Scientific Officer, n3D Biosciences), Igor Zlatkin (Application Scientist, Digilab), Kenneth Church (President and Chief Executive Officer, nScrypt) and Xudong Chen (Executive Vice President Business Development & Sales, nScrypt), Laura Bosworth (Chief Executive Officer and Co-founder, TeVido BioDevices), Lauralyn McDaniel (Industry Manager, SME), Marc Thurner (Chief Executive Officer, regenHU), Roger Narayan (Professor, North Carolina State University) and Simon Fried (Chief Business Officer, Nano Dimension). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
While the focus has been on forecasting the market till 2030, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the 3D bioprinting market in the mid to long term.
Chapter 3 provides a general overview of 3D bioprinting, covering its historical background, evolution and current applications. In addition, the section provides information on the material and technical requirements, and the process of bioprinting.
Chapter 4 provides a comprehensive market landscape of 3D bioprinters and bioprinted products that have already been developed and / or are under development. This chapter includes information on the developers, applications, technologies, details on different printing parameters (for instance, cell viability, precision, print speed and resolution) and the cost of bioprinters.
Chapter 5 presents profiles of some of the active players (based on the number of bioprinters / commercialized bioprinted products) in this domain, highlighting their expertise related to 3D bioprinters and bioprinted products. Each profile provides a brief overview of the company, 3D bioprinting devices and / or bioprinted products, its financial information (wherever available), recent developments and a comprehensive future outlook.
Chapter 6 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst stakeholders in this market. The chapter includes details on the different partnership models, such as research agreements, distribution agreements, product development agreements and licensing agreements that have been established in the period between 2012 and late 2017. In addition, we have presented details on the various investments and grants received by companies between 2012 to late 2017, highlighting the growing interest of the venture capital community and other strategic investors within this market.
Chapter 7 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of 3D bioprinting, under a comprehensive SWOT framework.
Chapter 8 provides insights on the popularity of 3D bioprinting on the social media platform, Twitter. The section features an analysis of the yearly distribution of tweets posted on the platform in the time period 2012 to late 2017, highlighting the most significant events responsible for the increase / decrease in the volume of tweets each year.
Chapter 9 provides insights on recent trends in the 3D bioprinting industry, such as scaffold-free printing, stem cell based bioinks, 4D bioprinting and advent of low-cost bioprinters, which are expected to influence the adoption of bioprinted products in the coming years.
Chapter 10 features a comparison of product competitiveness and supplier power of bioprinters in the form of a 2 x 2 matrix. The analysis takes into considerations several parameters such as type of technology and range of applications offered by these bioprinters.
Chapter 11 provides a detailed analysis of the patents that have been filed in the field of 3D bioprinting. The analysis highlights emerging trends in the intellectual property portfolio of this field, and identifies the key players that are driving innovation in this space.
Chapter 12 presents a comprehensive market forecast analysis, highlighting the future potential of 3D bioprinting, till the year 2035. We have segregated the opportunity on the basis of the type of application of the bioprinted product (drug testing / drug screening, tissue engineering / tissue implants and organ transplant), type of bioprinting technology (extrusion, inkjet, laser and others) and the geographical distribution of the market (North America, Europe, Asia Pacific and Rest of the World). The sales potential and future growth opportunity were estimated based on the target patient population, likely adoption rates and the likely price of products.
Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 14 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of discussions held with the following individuals:
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.